NO20015257D0 - Pharmaceutical composition to prevent, treat or developmentally inhibit simple retinopathy and preproliferative retinopathy - Google Patents

Pharmaceutical composition to prevent, treat or developmentally inhibit simple retinopathy and preproliferative retinopathy

Info

Publication number
NO20015257D0
NO20015257D0 NO20015257A NO20015257A NO20015257D0 NO 20015257 D0 NO20015257 D0 NO 20015257D0 NO 20015257 A NO20015257 A NO 20015257A NO 20015257 A NO20015257 A NO 20015257A NO 20015257 D0 NO20015257 D0 NO 20015257D0
Authority
NO
Norway
Prior art keywords
retinopathy
pharmaceutical composition
developmentally
treat
prevent
Prior art date
Application number
NO20015257A
Other languages
Norwegian (no)
Other versions
NO20015257L (en
NO327446B1 (en
Inventor
Shizue Nakagawa
Yasutaka Nagisha
Hitoshi Ikeda
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20015257D0 publication Critical patent/NO20015257D0/en
Publication of NO20015257L publication Critical patent/NO20015257L/en
Publication of NO327446B1 publication Critical patent/NO327446B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

To provide a pharmaceutical composition for preventing, treating or development-inhibiting simple retinopathy or preproliferative retinopathy, comprising a compound having angiotensin II antagonistic activity, or a salt thereof.
NO20015257A 1999-04-28 2001-10-26 Use of a compound having the antagonistic activity of angiotensin II, a prodrug thereof or a salt thereof. NO327446B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP12149899 1999-04-28
PCT/JP2000/002766 WO2000066161A1 (en) 1999-04-28 2000-04-27 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy

Publications (3)

Publication Number Publication Date
NO20015257D0 true NO20015257D0 (en) 2001-10-26
NO20015257L NO20015257L (en) 2001-10-26
NO327446B1 NO327446B1 (en) 2009-06-29

Family

ID=14812676

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015257A NO327446B1 (en) 1999-04-28 2001-10-26 Use of a compound having the antagonistic activity of angiotensin II, a prodrug thereof or a salt thereof.

Country Status (23)

Country Link
US (2) US7064141B1 (en)
EP (1) EP1197223B1 (en)
KR (1) KR100865059B1 (en)
CN (1) CN1172719C (en)
AT (1) ATE289204T1 (en)
AU (1) AU774799B2 (en)
BR (1) BR0010084A (en)
CA (1) CA2371554C (en)
CZ (1) CZ301913B6 (en)
DE (1) DE60018186T2 (en)
DK (1) DK1197223T3 (en)
ES (1) ES2233362T3 (en)
HU (1) HU226948B1 (en)
MX (1) MXPA01010923A (en)
NO (1) NO327446B1 (en)
NZ (1) NZ514855A (en)
PL (1) PL196895B1 (en)
PT (1) PT1197223E (en)
RU (1) RU2239454C2 (en)
SI (1) SI1197223T1 (en)
SK (1) SK286859B6 (en)
WO (1) WO2000066161A1 (en)
ZA (1) ZA200108527B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484427B2 (en) * 2001-12-03 2010-06-16 武田薬品工業株式会社 Insulin resistance improving agent
WO2003047573A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
TW200304812A (en) * 2002-03-08 2003-10-16 Sankyo Co An eye drop containing a tetrazole derivative
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (en) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis
BRPI0409293A (en) * 2003-04-15 2006-04-11 Sankyo Co medicine for the prevention or treatment of intraocular angiogenic diseases
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
KR20070083538A (en) 2004-08-31 2007-08-24 뉴사우스 이노베이션즈 피티와이 리미티드 Vegf inhibition
EA013053B1 (en) * 2004-11-05 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Bilayer tablet comprising telmisartan and amlodipine
DK1872783T3 (en) * 2005-04-21 2012-04-23 Santen Pharmaceutical Co Ltd Therapeutic agent for corneal / conjunctival disorders
RU2423127C2 (en) * 2005-12-06 2011-07-10 Сантен Фармасьютикал Ко., Лтд. Therapeutic medication against corneal-conjunctival disturbance
EA016593B1 (en) * 2007-03-28 2012-06-29 Такеда Фармасьютикал Компани Лимитед Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
DE4201554A1 (en) 1992-01-22 1993-07-29 Thomae Gmbh Dr K New benzimidazol-1-yl-methyl-bi:phenyl derivs.
GB9110635D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
GB9223860D0 (en) 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
CZ154994A3 (en) 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
JPH0789957A (en) 1993-09-22 1995-04-04 Nissan Chem Ind Ltd Biphenylmethylamine derivative
JPH09508641A (en) * 1994-02-08 1997-09-02 チバーガイギー アクチエンゲゼルシャフト Treatment of normal tension glaucoma with angiotensin II antagonist
JPH09210183A (en) * 1996-01-31 1997-08-12 Suzuki Motor Corp Power transmission
TR199801954T2 (en) * 1996-03-29 1998-12-21 Smithkline Beecham Corporation Eprosartan dihydrate and a process for its manufacture and formulation.
PL189066B1 (en) * 1996-04-05 2005-06-30 Takeda Pharmaceutical Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity
TW416953B (en) 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
EP0855392A3 (en) * 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agent and medicaments containing them
EP0991647B1 (en) 1997-06-27 2002-09-04 Smithkline Beecham Corporation Eprosartan monohydrate
IT1292437B1 (en) 1997-06-30 1999-02-08 Zambon Spa ORTHO-METALLATION PROCESS USEFUL FOR THE SYNTHESIS OF 1 - TETRAZOL- 5-IL) 2-SUBSTITUTED BENZENES
KR100508044B1 (en) * 1997-08-06 2005-08-17 스미스클라인 비참 코포레이션 Eprosartan Arginyl Charge-neutralization-complex and a Process for its Production and Formulation
ATE258430T1 (en) 1998-03-04 2004-02-15 Takeda Chemical Industries Ltd PREPARATION WITH DELAYED RELEASE FOR AII ANTAGONISTS, THEIR PRODUCTION AND USE
RU2243768C2 (en) * 1998-07-10 2005-01-10 Новартис Аг Hypotensive combination of valsartan and calcium channel blocking agent
FR2783422A1 (en) 1998-09-21 2000-03-24 Sanofi Sa Composition for reducing treating hypertension or platelet aggregation disorders, contains angiotensin II receptor antagonist and platelet anti-aggregation agent
JP2000159671A (en) 1998-12-01 2000-06-13 Takeda Chem Ind Ltd Arterialization inhibitor

Also Published As

Publication number Publication date
KR100865059B1 (en) 2008-10-23
EP1197223A1 (en) 2002-04-17
US7064141B1 (en) 2006-06-20
ATE289204T1 (en) 2005-03-15
PT1197223E (en) 2005-04-29
EP1197223A4 (en) 2003-10-29
DE60018186D1 (en) 2005-03-24
DE60018186T2 (en) 2005-12-29
CA2371554C (en) 2009-06-09
HUP0200890A3 (en) 2002-12-28
US20060189669A1 (en) 2006-08-24
ES2233362T3 (en) 2005-06-16
BR0010084A (en) 2002-01-15
AU774799B2 (en) 2004-07-08
NO20015257L (en) 2001-10-26
CZ301913B6 (en) 2010-07-28
MXPA01010923A (en) 2002-06-21
KR20020015315A (en) 2002-02-27
EP1197223B1 (en) 2005-02-16
PL350554A1 (en) 2002-12-16
CA2371554A1 (en) 2000-11-09
DK1197223T3 (en) 2005-05-30
SI1197223T1 (en) 2005-08-31
CN1172719C (en) 2004-10-27
ZA200108527B (en) 2002-10-17
HU226948B1 (en) 2010-03-29
RU2239454C2 (en) 2004-11-10
CZ20013804A3 (en) 2002-04-17
WO2000066161A1 (en) 2000-11-09
NZ514855A (en) 2004-01-30
SK15452001A3 (en) 2002-04-04
SK286859B6 (en) 2009-06-05
HUP0200890A2 (en) 2002-11-28
PL196895B1 (en) 2008-02-29
NO327446B1 (en) 2009-06-29
CN1348385A (en) 2002-05-08
AU4143400A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
GB9801690D0 (en) Therapeutic agents
BR9916798A (en) 4-arylamino, 4-aryloxy and 4-arylthio diarylamines and their derivatives as selective mek inhibitors
TR199902033T2 (en) Sulfonylura-glitazone synergistic combinations for diabetes.
DK0977741T3 (en) Substituted phenyl derivatives, their preparation and use
PT1214936E (en) USE OF TIAZOLIDINE OR PYRROLIDINE DERIVATIVES OF AMINOACIDES AS ANTI-HYPERGICEMIC AGENTS
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
DE59400489D1 (en) Fungicidal active ingredient combinations
DE60131138D1 (en) ANTIBACTERIAL AGENTS
NO20015257D0 (en) Pharmaceutical composition to prevent, treat or developmentally inhibit simple retinopathy and preproliferative retinopathy
ATE387215T1 (en) AGENT FOR PREVENTING OR TREATING PSORIASIS HAVING AN IL-6 ANTAGONIST AS THE ACTIVE INGREDIENT
EA200100731A1 (en) PHENYLPHENANTHRIDINE WITH INHIBITING FDE-4 ACTIVITY
DK0624583T3 (en) Substituted pyridylmethylpyridones as angiotensin II antagonists
SE0104248D0 (en) Method of treatment
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
BR0316085A (en) Microbicidal substances
TR200201245T2 (en) Oncolytic combinations for cancer treatment.
DE60008935D1 (en) PYRIDINE SULFONYL URINE DERIVATIVES WITH HERBICIDAL EFFECT
TR200000272T2 (en) O-substituted hydrocycumaranone derivatives as antitumor and antimetastatic agents.
ZA200308147B (en) Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals.
TR200201128T2 (en) Tetrahydrothiopyraniphalazinone derivatives as PDE4 inhibitors.
DK0842165T3 (en) Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
DK1015437T3 (en) Benzoxazine and benzothiazine derivatives and their use in pharmaceuticals
EE200200113A (en) Substituted N-Phenyl-2-Hydroxy-2-Methyl-3,3,3-Trifluoropropanamide Derivatives Enhancing Pyruvate Dehydrogenase Activity
BRPI0409718A (en) 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or its salt

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees